Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Celldex (TCE2) Stock Price & Analysis

TCE2 Stock Chart & Stats

€26.40€0.12(0.46%)
At close: 1:00 AM GMT+1
€27.5€30€32.5€3524 Aug25 Aug11 Sep22 Sep26 Oct
Day’s Range
EUR 26.40 - EUR 26.40
52-Week Range
EUR 18.90 - EUR 38.34
Previous Close
EUR 26.28
Volume
N/A
Average Volume (3M)
30
Market Cap
EUR 2.12B
Enterprise Value
EUR 2.19B
Total Cash (Recent Filing)
EUR 717.59M
Total Debt (Recent Filing)
EUR 4.90M
Price to Earnings (P/E)
―
Beta
0.74
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
-0.91
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase 3 Clinical Progress

Strong Phase 3 results materially improve barzolvolimab’s clinical and potential commercialization outlook. Efficacy was rapid, sustained, and observed in difficult-to-treat patients, while favorable safety through 24 weeks supports the candidate’s durability as Celldex advances toward commercialization.

Low Financial Leverage

Minimal debt reduces solvency and refinancing risk, which is especially valuable for an R&D-intensive biotech with unpredictable development timelines. The company’s sizable equity and asset base provides financial flexibility to continue clinical programs and absorb operating volatility.

Broad Antibody Pipeline

Celldex has a multi-program antibody pipeline spanning mast cell-driven disease, immunology, inflammation, and oncology. This breadth creates several potential avenues for clinical value creation and reduces reliance on a single therapeutic area, although each program remains development-stage.

Bears Say

Near-zero Commercial Scale

Near-zero trailing revenue shows that Celldex has not yet established meaningful commercial scale and remains dependent on financing or other non-recurring sources. This limits internal funding capacity and leaves future financial performance highly dependent on clinical and partnering outcomes.

Widening Losses

Persistent losses and worsening TTM results indicate that operating costs remain far ahead of revenue generation. Without successful development, regulatory progress, or commercialization, this cost structure can continue eroding the capital base and delay the path toward sustainable profitability.

Accelerating Cash Burn

Accelerating negative operating and free cash flow increases the company’s future funding requirements while its business remains unprofitable. Continued burn could require additional financing or collaboration proceeds, making execution and capital access important to sustaining the development pipeline.

Celldex News

TCE2 FAQ

What was Celldex’s price range in the past 12 months?
Celldex lowest stock price was €18.90 and its highest was €38.34 in the past 12 months.
What is Celldex’s market cap?
Celldex’s market cap is €2.12B.
When is Celldex’s upcoming earnings report date?
Celldex’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is in 9 days.
How were Celldex’s earnings last quarter?
Celldex released its earnings results on Aug 06, 2026. The company reported -€0.842 earnings per share for the quarter, beating the consensus estimate of -€0.946 by €0.105.
Is Celldex overvalued?
According to Wall Street analysts Celldex’s price is currently Undervalued.
Does Celldex pay dividends?
Celldex does not currently pay dividends.
What is Celldex’s EPS estimate?
Celldex’s EPS estimate is -0.91.
How many shares outstanding does Celldex have?
Celldex has 78,529,530 shares outstanding.
What happened to Celldex’s price movement after its last earnings report?
Celldex reported an EPS of -€0.842 in its last earnings report, beating expectations of -€0.946. Following the earnings report the stock price went up 3.886%.
Which hedge fund is a major shareholder of Celldex?
Hedge funds hold Celldex shares: the largest hedge-fund position in Celldex is 585,925,675 shares, and hedge funds increased their holdings by 1.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology